{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:59:22Z","timestamp":1771883962887,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Korean Government"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.canlet.2013.11.010","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T12:32:13Z","timestamp":1386765133000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor"],"prefix":"10.1016","volume":"345","author":[{"given":"Hyang Sook","family":"Seol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HyoJeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seul-I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Im","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Min","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang sik","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Ah","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shree Ram","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhwan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2010","key":"10.1016\/j.canlet.2013.11.010_b0005","first-page":"765","article-title":"Estimates of cancer incidence and mortality in Europe","volume":"46","author":"Ferlay","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2013.11.010_b0010","series-title":"Colorectal Cancer Facts & Figures 2011\u20132013","author":"American Cancer Society","year":"2011"},{"key":"10.1016\/j.canlet.2013.11.010_b0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymeth.2012.10.003","article-title":"RNA biomarkers in colorectal cancer","volume":"59","author":"Bustin","year":"2013","journal-title":"Methods"},{"key":"10.1016\/j.canlet.2013.11.010_b0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4166\/kjg.2013.61.3.128","article-title":"A perspective: role of targeted therapy in colon cancer","volume":"61","author":"Chung","year":"2013","journal-title":"Korean J. Gastroenterol."},{"key":"10.1016\/j.canlet.2013.11.010_b0025","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/stem.1163","article-title":"Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells","volume":"30","author":"Francescangeli","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.canlet.2013.11.010_b0030","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.canlet.2013.11.010_b0035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2013.11.010_b0040","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.11.010_b0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1878-5085-4-3","article-title":"Targeted therapies in colorectal cancer-an integrative view by PPPM","volume":"4","author":"Hagan","year":"2013","journal-title":"EPMA J."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2013.11.010_b0050","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3816\/CBC.2010.s.002","article-title":"Optimizing chemotherapy regimens for patients with early-stage breast cancer","volume":"10","author":"Dotan","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2013.11.010_b0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1053\/j.seminoncol.2010.05.012","article-title":"Drug development for cancer chemoprevention: focus on molecular targets","volume":"37","author":"Johnson","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2013.11.010_b0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JTO.0b013e31815efe24","article-title":"Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise","volume":"3","author":"Azzoli","year":"2008","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.canlet.2013.11.010_b0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ccr.2013.03.021","article-title":"Gain of interaction with IRS1 by p110\u03b1-helical domain mutants is crucial for their oncogenic functions","volume":"23","author":"Hao","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2013.11.010_b0070","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2013.11.010_b0075","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/sj.onc.1210850","article-title":"The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids","volume":"27","author":"De Witt Hamer","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.11.010_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/gcc.10300","article-title":"Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR","volume":"39","author":"Pandita","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2013.11.010_b0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2559.2006.02549.x","article-title":"Classification of colorectal cancer based on correlation of clinical, morphological and molecular features","volume":"50","author":"Jass","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2013.11.010_b0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-10-2224","article-title":"The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer","volume":"17","author":"John","year":"2011","journal-title":"Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2013.11.010_b0095","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-12-0372","article-title":"Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer","volume":"18","author":"Julien","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.11.010_b0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3892\/ijo.2012.1469","article-title":"Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases","volume":"41","author":"Jin","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2013.11.010_b0105","first-page":"126","article-title":"Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases","volume":"30","author":"Dong","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.canlet.2013.11.010_b0110","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","article-title":"Patient-derived tumor xenografts: transforming clinical samples into mouse models","volume":"73","author":"Siolas","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.11.010_b0115","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1078-0432.CCR-09-2878","article-title":"Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy","volume":"16","author":"Dong","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.11.010_b0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molonc.2013.02.004","article-title":"Patient-derived xenografts recapitulate molecular features of human uveal melanomas","volume":"7","author":"Laurent","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2013.11.010_b0125","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1158\/1078-0432.CCR-12-2408","article-title":"The promise of patient-derived xenografts: the best laid plans of mice and men","volume":"18","author":"Kopetz","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.11.010_b0130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/cancers4030821","article-title":"Characterization of the tumor-microenvironment in patient-derived cervix xenografts (OCICx)","volume":"4","author":"Chaudary","year":"2012","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2013.11.010_b0135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JTO.0b013e3182519d4d","article-title":"Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer","volume":"7","author":"John","year":"2012","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.canlet.2013.11.010_b0140","doi-asserted-by":"crossref","first-page":"e7887","DOI":"10.1371\/journal.pone.0007887","article-title":"Profiling critical cancer gene mutations in clinical tumor samples","volume":"4","author":"MacConaill","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2013.11.010_b0145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1479-5876-11-168","article-title":"Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies","volume":"11","author":"Zhang","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2013.11.010_b0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr3355","article-title":"Patient-derived breast tumor xenografts facilitating personalized cancer therapy","volume":"15","author":"Landis","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2013.11.010_b0155","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00432-013-1449-6","article-title":"A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically","volume":"139","author":"Seol","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.11.010_b0160","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2013.11.010_b0165","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ejca.2010.12.019","article-title":"Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance","volume":"47","author":"Krumbach","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2013.11.010_b0170","first-page":"567","article-title":"Patient-derived xenografts of non-small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells","author":"Moro","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.canlet.2013.11.010_b0175","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.88.20.9345","article-title":"Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens","volume":"88","author":"Fu","year":"1991","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2013.11.010_b0180","first-page":"105","article-title":"Feasibility and limits of an orthotopic human colon cancer model in nude mice","volume":"56","author":"Thalheimer","year":"2006","journal-title":"Comp. Med."},{"key":"10.1016\/j.canlet.2013.11.010_b0185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.canlet.2013.04.034","article-title":"Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models","volume":"337","author":"Adiseshaiah","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2013.11.010_b0190","first-page":"435","article-title":"Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide","volume":"29","author":"Flis","year":"2009","journal-title":"Anticancer Res."}],"updated-by":[{"DOI":"10.1016\/j.canlet.2014.02.021","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513008197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513008197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:35:11Z","timestamp":1759592111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513008197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0304383513008197"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.11.010","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}